Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
110.2 PLN | -3.01% | -0.98% | -23.49% |
16/07 | ORIC Pharmaceuticals, Inc. Enters into Clinical Trial Collaboration and Supply Agreements with Bayer and Janssen Research & Development, LLC | CI |
15/07 | BAYER AG : UBS sticks Neutral | ZD |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
Strengths
- With a P/E ratio at 10.98 for the current year and 7.75 for next year, earnings multiples are highly attractive compared with competitors.
- The company's share price in relation to its net book value makes it look relatively cheap.
- Given the positive cash flows generated by its business, the company's valuation level is an asset.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
- The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- Over the past twelve months, analysts' opinions have been revised negatively.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-23.49% | 28.29B | - | ||
+61.53% | 856B | C+ | ||
+38.95% | 631B | B | ||
-3.66% | 359B | C+ | ||
+15.06% | 325B | B- | ||
+9.18% | 297B | C+ | ||
+5.89% | 234B | A+ | ||
+16.53% | 226B | B- | ||
+15.67% | 177B | C+ | ||
+2.47% | 165B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- BAYN Stock
- BAY Stock
- Ratings Bayer AG